<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052494</url>
  </required_header>
  <id_info>
    <org_study_id>PMH-PHL-008</org_study_id>
    <secondary_id>CDR0000258487</secondary_id>
    <secondary_id>NCI-5684</secondary_id>
    <nct_id>NCT00052494</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Study Of STI 571 (Gleevec) In Combination With Cisplatin/Irinotecan In Patients With Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die. Imatinib mesylate may stop the growth of tumor cells by&#xD;
      blocking the enzymes necessary for their growth. Combining more than one chemotherapy drug&#xD;
      with imatinib mesylate may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining cisplatin, irinotecan, and&#xD;
      imatinib mesylate in treating patients who have extensive-stage small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of imatinib mesylate when administered with&#xD;
           cisplatin and irinotecan in patients with extensive stage small cell lung cancer.&#xD;
&#xD;
        -  Determine the recommended phase II dose of imatinib mesylate in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the response rate, median duration of response, progression-free survival,&#xD;
           median survival, and overall survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of imatinib mesylate.&#xD;
&#xD;
      Patients receive cisplatin IV over 1 hour on day 1 and irinotecan IV over 60 minutes on days&#xD;
      1, 8, and 15. Treatment repeats every 28 days for a maximum of 4 courses. Patients also&#xD;
      receive oral imatinib mesylate daily continually for one week prior to, during, and after&#xD;
      chemotherapy in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of imatinib mesylate until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD is determined, additional patients&#xD;
      are treated at the recommended phase II dose (one dose level below the MTD).&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-24 patients will be accrued for this study within 1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>STI-571 with cisplatin and irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>STI-571 with cisplatin and irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <arm_group_label>STI-571 with cisplatin and irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>STI-571 with cisplatin and irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed extensive stage small cell lung cancer&#xD;
&#xD;
               -  Incurable but amenable to treatment with chemotherapy&#xD;
&#xD;
               -  c-kit positive by immunohistochemistry of original biopsy or other metastatic&#xD;
                  site&#xD;
&#xD;
          -  At least one unidimensionally measurable lesion&#xD;
&#xD;
               -  &gt; 20 mm by conventional techniques or &gt; 10 mm by spiral CT scan&#xD;
&#xD;
               -  No prior radiotherapy to target measurable lesion(s), unless there is documented&#xD;
                  disease progression&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1 OR&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and/or ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No concurrent untreated upper gastrointestinal bleeding that has not been fully&#xD;
             investigated&#xD;
&#xD;
          -  No gastrointestinal disease that would impair drug absorption&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception prior to, during, and for 3&#xD;
             months after study participation&#xD;
&#xD;
          -  No history of ototoxicity&#xD;
&#xD;
          -  No history of peripheral neuropathy&#xD;
&#xD;
          -  No traumatic injury within the past 21 days&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No other concurrent significant medical condition that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No concurrent psychiatric condition or social situation that would preclude study&#xD;
             compliance&#xD;
&#xD;
          -  No other malignancy within the past 5 years except treated nonmelanoma skin cancer,&#xD;
             carcinoma in situ, or stage A prostate cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of marrow&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 3 weeks since prior major surgery&#xD;
&#xD;
          -  No prior surgical procedure impairing absorption&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior c-kit-targeted therapy&#xD;
&#xD;
          -  No concurrent therapeutic dose of warfarin&#xD;
&#xD;
               -  Mini-dose warfarin for prophylaxis and low-molecular weight heparin allowed&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent amifostine&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D. Vincent, MD</last_name>
    <role>Study Chair</role>
    <affiliation>London Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

